메뉴 건너뛰기




Volumn 78, Issue 1, 2010, Pages 213-220

Sorafenib and radiation: A promising combination in colorectal cancer

Author keywords

Growth delay; Radiation; Sorafenib; Targeted agents; Xenograft

Indexed keywords

ANGIOGENESIS; CELL SURVIVAL; CLONOGENIC ASSAYS; CLONOGENIC SURVIVAL ASSAYS; COLORECTAL CANCER; COLORECTAL CANCER CELL; COMBINED TREATMENT; GROWTH DELAY; GROWTH INHIBITION; IN-VITRO; IN-VIVO; MINIMAL EFFECTS; MTT ASSAYS; OPTIMAL TIMING; RADIATION RESPONSE; SORAFENIB; TARGETED AGENTS; THRESHOLD VOLUME; TUMOR SIZE; XENOGRAFT;

EID: 77955904732     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.02.064     Document Type: Article
Times cited : (29)

References (35)
  • 1
    • 4944249117 scopus 로고    scopus 로고
    • BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    • S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
    • (2004) Cancer Res , vol.64 , pp. 7099-7109
    • Wilhelm, S.M.1    Carter, C.2    Tang, L.3
  • 2
    • 47049094020 scopus 로고    scopus 로고
    • Metastatic melanoma: Scientific rationale for sorafenib treatment and clinical results
    • F. Egberts, K.C. Kahler, and E. Livingstone Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results Onkologie 31 2008 398 403
    • (2008) Onkologie , vol.31 , pp. 398-403
    • Egberts, F.1    Kahler, K.C.2    Livingstone, E.3
  • 3
    • 33846260566 scopus 로고    scopus 로고
    • Sorafenib for the treatment of advanced renal cell carcinoma
    • R.C. Kane, A.T. Farrell, and H. Saber Sorafenib for the treatment of advanced renal cell carcinoma Clin Cancer Res 12 2006 7271 7278
    • (2006) Clin Cancer Res , vol.12 , pp. 7271-7278
    • Kane, R.C.1    Farrell, A.T.2    Saber, H.3
  • 4
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 5
    • 33846212284 scopus 로고    scopus 로고
    • Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    • L. Liu, Y. Cao, and C. Chen Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 2006 11851 11858
    • (2006) Cancer Res , vol.66 , pp. 11851-11858
    • Liu, L.1    Cao, Y.2    Chen, C.3
  • 6
    • 39149129114 scopus 로고    scopus 로고
    • Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia
    • W. Zhang, M. Konopleva, and Y.X. Shi Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia J Natl Cancer Inst 100 2008 184 198
    • (2008) J Natl Cancer Inst , vol.100 , pp. 184-198
    • Zhang, W.1    Konopleva, M.2    Shi, Y.X.3
  • 7
    • 52749099497 scopus 로고    scopus 로고
    • Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
    • H. Linardou, I.J. Dahabreh, and D. Kanaloupiti Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 2008 962 972
    • (2008) Lancet Oncol , vol.9 , pp. 962-972
    • Linardou, H.1    Dahabreh, I.J.2    Kanaloupiti, D.3
  • 8
    • 38049019119 scopus 로고    scopus 로고
    • Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials
    • C.H. Takimoto, and A. Awada Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials Cancer Chemother Pharmacol 61 2008 535 548
    • (2008) Cancer Chemother Pharmacol , vol.61 , pp. 535-548
    • Takimoto, C.H.1    Awada, A.2
  • 9
    • 51049098909 scopus 로고    scopus 로고
    • Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors
    • L. Dal Lago, V. D'Hondt, and A. Awada Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors Oncologist 13 2008 845 858
    • (2008) Oncologist , vol.13 , pp. 845-858
    • Dal Lago, L.1    D'Hondt, V.2    Awada, A.3
  • 10
    • 34250218226 scopus 로고    scopus 로고
    • Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab
    • D. Curran, J. Giralt, and P.M. Harari Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab J Clin Oncol 25 2007 2191 2197
    • (2007) J Clin Oncol , vol.25 , pp. 2191-2197
    • Curran, D.1    Giralt, J.2    Harari, P.M.3
  • 11
    • 32144433159 scopus 로고    scopus 로고
    • Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    • J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
    • (2006) N Engl J Med , vol.354 , pp. 567-578
    • Bonner, J.A.1    Harari, P.M.2    Giralt, J.3
  • 12
    • 34748831698 scopus 로고    scopus 로고
    • Biology of interactions: Antiepidermal growth factor receptor agents
    • P.M. Harari, G.W. Allen, and J.A. Bonner Biology of interactions: Antiepidermal growth factor receptor agents J Clin Oncol 25 2007 4057 4065
    • (2007) J Clin Oncol , vol.25 , pp. 4057-4065
    • Harari, P.M.1    Allen, G.W.2    Bonner, J.A.3
  • 13
    • 35148842941 scopus 로고    scopus 로고
    • Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation
    • J.P. Plastaras, S.H. Kim, and Y.Y. Liu Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation Cancer Res 67 2007 9443 9454
    • (2007) Cancer Res , vol.67 , pp. 9443-9454
    • Plastaras, J.P.1    Kim, S.H.2    Liu, Y.Y.3
  • 14
    • 33748676449 scopus 로고    scopus 로고
    • Chemotherapy with preoperative radiotherapy in rectal cancer
    • J.F. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
    • (2006) N Engl J Med , vol.355 , pp. 1114-1123
    • Bosset, J.F.1    Collette, L.2    Calais, G.3
  • 15
    • 33750580102 scopus 로고    scopus 로고
    • Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203
    • J.P. Gerard, T. Conroy, and F. Bonnetain Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203 J Clin Oncol 24 2006 4620 4625
    • (2006) J Clin Oncol , vol.24 , pp. 4620-4625
    • Gerard, J.P.1    Conroy, T.2    Bonnetain, F.3
  • 16
    • 6044226542 scopus 로고    scopus 로고
    • Preoperative versus postoperative chemoradiotherapy for rectal cancer
    • R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
    • (2004) N Engl J Med , vol.351 , pp. 1731-1740
    • Sauer, R.1    Becker, H.2    Hohenberger, W.3
  • 17
    • 70449726857 scopus 로고    scopus 로고
    • Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03
    • M.S. Roh, L.H. Colangelo, and M.J. O'Connell Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03 J Clin Oncol 27 2009 5124 5130
    • (2009) J Clin Oncol , vol.27 , pp. 5124-5130
    • Roh, M.S.1    Colangelo, L.H.2    O'Connell, M.J.3
  • 18
    • 64649083998 scopus 로고    scopus 로고
    • Phase i trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients
    • L. Ugidos, S. Delgado, and C. Conill Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients Invest New Drugs 27 2009 262 268
    • (2009) Invest New Drugs , vol.27 , pp. 262-268
    • Ugidos, L.1    Delgado, S.2    Conill, C.3
  • 19
    • 34648814228 scopus 로고    scopus 로고
    • Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group
    • G.A. Hospers, C.J. Punt, and M.E. Tesselaar Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group Ann Surg Oncol 14 2007 2773 2779
    • (2007) Ann Surg Oncol , vol.14 , pp. 2773-2779
    • Hospers, G.A.1    Punt, C.J.2    Tesselaar, M.E.3
  • 20
    • 67149086939 scopus 로고    scopus 로고
    • Molecular targeted treatment and radiation therapy for rectal cancer
    • F. Marquardt, F. Rodel, and G. Capalbo Molecular targeted treatment and radiation therapy for rectal cancer Strahlenther Onkol 185 2009 371 378
    • (2009) Strahlenther Onkol , vol.185 , pp. 371-378
    • Marquardt, F.1    Rodel, F.2    Capalbo, G.3
  • 21
    • 0142011609 scopus 로고    scopus 로고
    • Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels
    • R. Kopp, E. Rothbauer, and E. Mueller Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels Dis Colon Rectum 46 2003 1391 1399
    • (2003) Dis Colon Rectum , vol.46 , pp. 1391-1399
    • Kopp, R.1    Rothbauer, E.2    Mueller, E.3
  • 22
    • 34547445551 scopus 로고    scopus 로고
    • Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
    • F. Bertolini, C. Bengala, and L. Losi Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy Int J Radiat Oncol Biol Phys 68 2007 1455 1461
    • (2007) Int J Radiat Oncol Biol Phys , vol.68 , pp. 1455-1461
    • Bertolini, F.1    Bengala, C.2    Losi, L.3
  • 23
    • 18344388638 scopus 로고    scopus 로고
    • An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation
    • S. Cascinu, F. Graziano, and V. Catalano An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation Br J Cancer 86 2002 744 749
    • (2002) Br J Cancer , vol.86 , pp. 744-749
    • Cascinu, S.1    Graziano, F.2    Catalano, V.3
  • 24
    • 34247848005 scopus 로고    scopus 로고
    • Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase i trial results
    • B.G. Czito, J.C. Bendell, and C.G. Willett Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results Int J Radiat Oncol Biol Phys 68 2007 472 478
    • (2007) Int J Radiat Oncol Biol Phys , vol.68 , pp. 472-478
    • Czito, B.G.1    Bendell, J.C.2    Willett, C.G.3
  • 25
    • 11144354392 scopus 로고    scopus 로고
    • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
    • C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147
    • (2004) Nat Med , vol.10 , pp. 145-147
    • Willett, C.G.1    Boucher, Y.2    Di Tomaso, E.3
  • 26
    • 33750360895 scopus 로고    scopus 로고
    • Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice
    • C.G. Willett, S.V. Kozin, and D.G. Duda Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice Semin Oncol 33 2006 S35 S40
    • (2006) Semin Oncol , vol.33
    • Willett, C.G.1    Kozin, S.V.2    Duda, D.G.3
  • 27
    • 59949091448 scopus 로고    scopus 로고
    • Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    • C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
    • (2009) J Clin Oncol , vol.27 , pp. 663-671
    • Bokemeyer, C.1    Bondarenko, I.2    Makhson, A.3
  • 28
    • 63849088630 scopus 로고    scopus 로고
    • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    • E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
    • (2009) N Engl J Med , vol.360 , pp. 1408-1417
    • Van Cutsem, E.1    Kohne, C.H.2    Hitre, E.3
  • 29
    • 64049090889 scopus 로고    scopus 로고
    • Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
    • V. Heinemann, S. Stintzing, and T. Kirchner Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR Cancer Treat Rev 35 2009 262 271
    • (2009) Cancer Treat Rev , vol.35 , pp. 262-271
    • Heinemann, V.1    Stintzing, S.2    Kirchner, T.3
  • 30
    • 42149083899 scopus 로고    scopus 로고
    • Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
    • L. Barault, N. Veyrie, and V. Jooste Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers Int J Cancer 122 2008 2255 2259
    • (2008) Int J Cancer , vol.122 , pp. 2255-2259
    • Barault, L.1    Veyrie, N.2    Jooste, V.3
  • 31
    • 55049136730 scopus 로고    scopus 로고
    • Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies
    • T.E. Hutson, R.A. Figlin, and J.G. Kuhn Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies Oncologist 13 2008 1084 1096
    • (2008) Oncologist , vol.13 , pp. 1084-1096
    • Hutson, T.E.1    Figlin, R.A.2    Kuhn, J.G.3
  • 32
    • 0034084314 scopus 로고    scopus 로고
    • Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
    • S.M. Huang, and P.M. Harari Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis Clin Cancer Res 6 2000 2166 2174
    • (2000) Clin Cancer Res , vol.6 , pp. 2166-2174
    • Huang, S.M.1    Harari, P.M.2
  • 33
    • 18044387648 scopus 로고    scopus 로고
    • Raf kinase as a target for anticancer therapeutics
    • S.S. Sridhar, D. Hedley, and L.L. Siu Raf kinase as a target for anticancer therapeutics Mol Cancer Ther 4 2005 677 685
    • (2005) Mol Cancer Ther , vol.4 , pp. 677-685
    • Sridhar, S.S.1    Hedley, D.2    Siu, L.L.3
  • 34
    • 33748063941 scopus 로고    scopus 로고
    • Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
    • J.A. McCubrey, L.S. Steelman, and S.L. Abrams Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Adv Enzyme Regul 46 2006 249 279
    • (2006) Adv Enzyme Regul , vol.46 , pp. 249-279
    • McCubrey, J.A.1    Steelman, L.S.2    Abrams, S.L.3
  • 35
    • 16644397086 scopus 로고    scopus 로고
    • The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells
    • W.Y. Tang, S.P. Chau, and W.P. Tsang The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells Oncol Rep 12 2004 1349 1354
    • (2004) Oncol Rep , vol.12 , pp. 1349-1354
    • Tang, W.Y.1    Chau, S.P.2    Tsang, W.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.